Abstract
To assess the genetic factors contributing to daptomycin resistance in Staphylococcus aureus, the draft genome of a clinically derived daptomycin-nonsusceptible isolate APS211 was generated and compared to the draft sequence of its susceptible progenitor strain APS210. Four genetic differences were identified including a previously described mutation within the mprF gene.
GENOME ANNOUNCEMENT
Daptomycin is a cyclic lipopeptide antibiotic that is increasingly relied upon for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections (1). Daptomycin-nonsusceptible strains (defined by a MIC > 1.0 µg/mL) have recently been described, however, the genetic mechanism behind the emergence of these strains is not completely understood (2, 3). We, and others, have performed whole-genome sequencing of daptomycin-exposed strains, identifying point mutations in numerous genes including those important for phospholipid metabolism (most notably the lysl-phosphatidylglycerol synthase, encoded by mprF), as well as the two-component regulatory system, walKR, and RNA polymerase subunits rpoB and rpoC (2, 4–6). In order to further understand the development of daptomycin resistance in S. aureus, we prepared the draft genome sequence of a daptomycin-susceptible strain, APS210 (daptomycin MIC 0.5 µg/mL), isolated from a patient with bacteremia and compared it to its daptomycin nonsusceptible derivative, APS211 (daptomycin MIC 4.0 µg/mL), that emerged after daptomycin treatment and therapeutic failure.
Genomic DNA from APS210 and APS211 was prepared using a QIAGEN blood and tissue kit per the manufacturer’s instructions and sequenced using Illumina MiSeq (250-bp paired-end reads) generating 5,255,342 and 4,468,075 reads, respectively. Draft genomes were assembled de novo using CLC workbench (v6.0.2) with >1,000× coverage and each genome was annotated using the NCBI Prokaryotic Genomes Annotation Pipeline. The genome sequence of APS210 comprised 83 contigs (>500 bp in length, N50 = 74,505 bp) with a combined length of 2,906,880 bp, G+C content of 32.7%, and 2,859 predicted protein-coding regions. The sequence of APS211 comprised 72 contigs (>500 bp in length, N50 = 73,502 bp) with a combined length of 2,905,661 bp and G+C content of 32.7%. Both strains were sequence type (ST) 45 and staphylococcal cassette chromosome mec (SCCmec) type V (7). Comparison of the two genomes revealed four single nucleotide polymorphisms (SNPs) including a mutation that led to the previously described MprF amino acid substitution, S337L (2, 8). Two of the SNPs were predicted to be synonymous within hypothetical proteins (a predicted phage protein and a protein with similarity to N-acyl-l-amino acid amidohydrolase) and the final SNP was predicted to be intergenic. Defining the precise molecular mechanisms behind MprF-mediated daptomycin-nonsusceptibility in S. aureus is ongoing in our laboratory.
Nucleotide sequence accession numbers.
The whole-genome shotgun sequences of APS210 and APS211 have been deposited in DDBJ/EMBL/GenBank under the accession numbers JXUD00000000 and JXUV00000000, respectively.
ACKNOWLEDGMENT
This study was supported by Australian National Health and Medical Research Council (NHMRC) project grant APP1047918.
Footnotes
Citation Cameron DR, Jiang J-H, Abbott IJ, Spelman DW, Peleg AY. 2015. Draft genome sequences of clinical daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus strain APS211 and its daptomycin-susceptible progenitor APS210. Genome Announc 3(3):e00568-15. doi:10.1128/genomeA.00568-15.
REFERENCES
- 1.Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fatkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355:653–665. doi: 10.1056/NEJMoa053783. [DOI] [PubMed] [Google Scholar]
- 2.Peleg AY, Miyakis S, Ward DV, Earl AM, Rubio A, Cameron DR, Pillai S, Moellering RC Jr, Eliopoulos GM. 2012. Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus. PLoS One 7:e28316. doi: 10.1371/journal.pone.0028316. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Hayden MK, Rezai K, Hayes RA, Lolans K, Quinn JP, Weinstein RA. 2005. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 43:5285–5287. doi: 10.1128/JCM.43.10.5285-5287.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Jones T, Yeaman MR, Sakoulas G, Yang SJ, Proctor RA, Sahl HG, Schrenzel J, Xiong YQ, Bayer AS. 2008. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother 52:269–278. doi: 10.1128/AAC.00719-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Yang SJ, Mishra NN, Rubio A, Bayer AS. 2013. Causal role of single nucleotide polymorphisms within the mprF gene of Staphylococcus aureus in daptomycin resistance. Antimicrob Agents Chemother 57:5658–5664. doi: 10.1128/AAC.01184-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Friedman L, Alder JD, Silverman JA. 2006. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother 50:2137–2145. doi: 10.1128/AAC.00039-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Ito T, Ma XX, Takeuchi F, Okuma K, Yuzawa H, Hiramatsu K. 2004. Novel type V staphylococcal cassette chromosome mec driven by a novel cassette chromosome recombinase, ccrC. Antimicrob Agents Chemother 48:2637–2651. doi: 10.1128/AAC.48.7.2637-2651.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Pillai SK, Gold HS, Sakoulas G, Wennersten C, Moellering RC Jr, Eliopoulos GM. 2007. Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF. Antimicrob Agents Chemother 51:2223–2225. doi: 10.1128/AAC.00202-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
